Makes sense

…company is simply too expensive — we can’t run the trial unless someone provides the drug for free. That gives the companies a lot of say in what trials get done, and it seems that most pharma companies have reached the same conclusion: a head-to-head trial is too risky. Be happy with the market share you have and try to nibble away at the edges through good old-fashio…
We Finally Got an Ozempic vs. Mounjaro Study
941
8
F. Perry Wilson, MD MSCE
Daniel Hopper
·Follow
Jul 10, 2024
--
Makes sense
--
--
Written by Daniel Hopper23K Followers
·463 Following
A marketer and gym addict who shares their knowledge and passion of these things and more. | linktr.ee/BYB_Marketing | Inquiries danz_nz@hotmail.com
No responses yet
Help
Status
About
Careers
Press
Blog
Privacy
Terms
Text to speech
Teams